KCI807

Research use only, not for human use.

KCI807 (KCI-807) is a lead molecule that selectively disrupts ELK1-dependent promoter activation by wild-type and variant Ars (IC50=0.53 uM).

KCI807 (KCI-807) is a lead molecule that selectively disrupts ELK1-dependent promoter activation by wild-type and variant Ars (IC50=0.53 uM) without interfering with ELK1 activation by ERK; binds to AR (Kd=69.2 nM), blocking ELK1 binding, and selectively blocks recruitment of AR to chromatin by ELK1; primarily affects a subset of AR target growth genes selectively suppressing AR-dependent growth of PC cell lines with a better inhibitory profile than Enzalutamide; also inhibits in vivo growth of castration/enzalutamide-resistant cell line-derived and patient-derived tumor xenografts.

——

——

KCI-807 | KCI 807

Endocrinology/Hormones

Androgen Receptor (AR)

Androgen Receptor (AR)

——

——

6665-68-5

254.241

C15H10O4

>98% (HPLC)

——

C1=CC(=CC(=C1)O)C2=CC(=O)C3=C(C=CC=C3O2)O

5-hydroxy-2-(3-hydroxyphenyl)-4H-chromen-4-one

(-20℃)

With Ice Pack

≥ 2 years